Author: James Love

A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing “junk patents.” The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they Continue Reading →

Attached in the February 7, 2014, KEI Special 301 Submission.

KEI was a web page with more context on the Special 301 reports, including links to several submissions, and all Special 301 Reports from 1989 to 2013 (all that exist), here: /ustr/special301 Continue Reading →

Three NGOs, Medicus Mundi International, HAI and MSF, each read statements during the EB discussions on the CEWG demonstration projects. The statements were limited to 300 words, and NGOs were required to provide the text 24 hours before the agenda item, and obtain WHO approval of the content. KEI worked with HAI on its statement, and the Peoples Health Movement worked with MMI on its statement. The text of the HAI and MMI statements follow:

Health Action International (HAI) statement to EB 134 On agenda item 9.3, follow up to CEWG on financing and coordination

Continue Reading →

Continue Reading →

Final conclusions, as approved, for meeting of WIPO SCCR 26

Posted on December 22, 2013 by James Love

Below is the final version of the conclusions from SCCR 26 (followed at the end with a short KEI commentary).

---

————
World Intellectual Property Organization (WIPO)
Standing Committee on Copyright and Related Rights (SCCR)
Twenty–sixth Session
Geneva, December 20, 2013

Conclusions

Protection of Broadcasting Organizations

Continue Reading →

Proposed conclusions to SCCR 26

Posted on December 21, 2013 by James Love

See PDF attachment. Note that PDF has pages 2 and 3 out of order. Continue Reading →

James K. Glassman. Merck said Glassman’s public relations firm was selected by PhRMA to lead a campaign to keep drug prices high in South Africa. The Health Minister in South Africa referred to the campaign proposal as a genocidal conspiracy of satanic magnitude.